MorphoSys offers the transfer and installation of the HuCAL GOLD
library and the AutoCAL automated screening system at the premises of
its clients, for the purpose of generating antibody reagents as well as
therapeutic and diagnostic antibody candidates. This offer includes a
comprehensive training for prospective users, the HuCAL user manual and
a specialized customer support. In return, MorphoSys receives
technology access and research license fees. For commercial use,
MorphoSys also receives development milestones and royalties on end
products. Technology licensing agreements currently exist with
companies including Bayer Schering, Daiichi-Sankyo, Schering-Plough,
Merck & Co. Inc., Shionogi and XOMA.
